6 TECH OUTLOOKNovember - 2020EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comHistorically, discovering new therapeutics involved ingredients extraction from natural products and followed by basic research to find potential treatments. With this process, the progress was generally slow, highly labor-intensive, and often frustrating. However, in the past few decades, massive improvements in computing power, advances in robotics, biological techniques, and enhanced methodologies in synthetic chemistry have catapulted the drug discovery process to high-throughput screening for known disease-associated targets.In the same vein, AI-enabled solutions have also been revolutionizing the understanding of disease mechanisms and how drugs bind to targets. AI can also help cross-reference published scientific papers with clinical trial information, public databanks, and unpublished datasets faster--with lesser manual efforts and higher levels of accuracy. Simultaneously, AI applications are also being used for drug target identification, drug screening, image screening, and predictive modeling. By leveraging machine learning, AI can manage disparate clinical trial datasets, enable virtual screening, and analyze vast amounts of data. Besides reducing clinical trial costs, AI can gain otherwise unobtainable insights and feed them back into the drug development process.In this edition of Pharma Tech Outlook, we bring you the story of some of the most prominent organizations specializing in drug discovery and development, and are significant drivers of key trends and strategies. Besides, the magazine also offers a combination of thought leadership articles from subject matter experts and exclusive insights from CXOs. We hope this edition will provide you with the right assistance in choosing the best drug discovery and development solution providers and consulting/service companies according to your requirements.Let us know your thoughts!AI: Revolutionizing Biologics DevelopmentCopyright © 2020 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.NOVEMBER - 09 - 2020, Vol 06 - Issue 25 (ISSN 2644-2787) Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405John GothamTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >